ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/BCL2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/BCL2-inhibitor
41
trial(s) found.
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia Previously Exposed to Both BTK and BCL2 Inhibitors (
BGB-16673-302
)
BCL2 inhibitor
BTK PROTAC degrader
PI3K-delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6005 - West Perth - Perth Blood Institute
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT06756932
Advanced
Phase 1
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer (
BGB-21447-102
)
BCL2 inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BCL2 inhibitor
BTK inhibitor
placebo
B-cell lymphoma
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06697184
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies. (
BGB-11417-108
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
6168 - Cooloongup - Rockingham Hospital
NCT06634589
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
+ BCL2 inhibitor
B-cell lymphoma
B-cell malignancy
Cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06563804
Haem
Phase 1 / Phase 2
Recruiting
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML) (
S227928-180
)
BCL2 inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06508489
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies (
TCD17796
)
NKp46-based NK-cell engager
+ BCL2 inhibitor
Acute myeloid leukaemia
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06456463
Haem
Phase 2
Recruiting
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (
TRILLIUM
)
BCL2 inhibitor
DNA methyltransferase inhibitor
IL-3 diphtheria toxin fusion protein
antimetabolite
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
M24-287
)
BCL2 inhibitor
BTK inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4812 - Townsville - Townsville University Hospital
NCT06291220
Haem
Phase 1
Recruiting
A Phase 1 Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-453 in Adult Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (
453-Ph1-CLL
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT05952037
Haem
Phase 2
Recruiting
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia (
BGB-11417-203
)
BCL2 inhibitor
BTK inhibitor
Waldenström Macroglobulinaemia
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Linear Clinical Research
NCT05947851
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
1026-010
)
BCL2 inhibitor
BTK inhibitor
anti-CD20 monoclonal antibody
Leukaemia
Lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05828589
Haem
Phase 1
Recruiting
A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies (
BGB-21447-101
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05756322
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (
LBS-007-CT01
)
CDC7 inhibitor
+ BCL2 inhibitor
Leukaemia
NSW
2500 - Wollongong - Wollongong Private Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT05453903
Haem
Phase 1
Recruiting
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (
CR109124
)
KMT2A inhibitor
+ BCL2 inhibitor
Acute myeloid leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
BCL2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (COMPLETED)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05005299
Haem
Phase 1
Recruiting
The
VICTORY
Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
BCL2 inhibitor
Leukaemia
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04973605
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
+ BCL2 inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04964518
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
BCL2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04895436
Haem
Phase 2
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia (
ReVenG
)
BCL2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
BCL2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital (COMPLETED)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
+ BCL2 inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT03850574
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (
TUSCANY
)
Azacitidine
BCL2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,BCL2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
+ BCL2 inhibitor
Chronic myelomonocytic leukaemia
Leukaemia
Myelodysplastic syndrome
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4812 - Townsville - Townsville University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03557619
Advanced
Phase 1
Recruiting
A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies (
M16-185
)
BCL2 inhibitor
Haematological malignancy
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
NCT03537482
Advanced
Phase 1
Recruiting
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies (
APG2575-001
)
BCL2 inhibitor
Haematological malignancy
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624000141549
Haem
Phase 1 / Phase 2
Not yet recruiting
AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (
AMLM26-T2
)
BCL2 inhibitor
IDH1 R132 inhibitor
Acute myeloid leukaemia
ACTRN12624000082505
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (
AMLM26-T1--INTERCEPT
)
AXL/FLT3 inhibitor
BCL2 inhibitor
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000065594
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain
Azacitidine
BCL2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,BCL2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
+ BCL2 inhibitor
Acute myeloid leukaemia
ACTRN12624000006549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (
AMLM26-T3-INTERCEPT
)
BCL2 inhibitor
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000900617
Haem
Not Applicable
Not yet recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
BCL2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12623000640606
Haem
Phase 2
Not yet recruiting
CLL08 - A phase 2 study of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory CLL patients with disease progression following VenR as their last line of therapy
BCL2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
ACTRN12622001158752
Haem
Phase 1 / Phase 2
Recruiting
MM25: A phase 1b/II study of the efficacy of Venetoclax, Iberdomide and Dexamethasone (IberVenD) for patients in first or second relapse of Multiple Myeloma with t(11;14) (
ALLG-Viber-M-MM25
)
BCL2 inhibitor
CELMoD agent
glucocorticoid
Multiple myeloma
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12619001655134
Haem
Phase 2
Recruiting
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (
INTERVENE
) Acute Myeloid Leukaemia
BCL2 inhibitor
Acute myeloid leukaemia
ACTRN12619000746134
Haem
Phase 2
Recruiting
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia
BCL2 inhibitor
antimetabolite
Acute myeloid leukaemia
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12619000280101
Haem
Phase 2
Recruiting
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC). (
AMLM22-D2
)
BCL2 inhibitor
antimetabolite
Acute myeloid leukaemia
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
ACTRN12616000445471
Haem
Phase 1 / Phase 2
Recruiting
A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid Leukemia (
CAVEAT
)
BCL2 inhibitor
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05665530
Haem
Phase 1
Active not recruiting
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies (
PRT2527-02
)
BCL2 inhibitor
BTK inhibitor
Acute myeloid leukaemia
Cancer
Chronic lymphocytic leukaemia
Chronic myelomonocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Myelodysplastic syndrome
Myeloproliferative Neoplasm
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
T-cell lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05308654
Haem
Phase 1
Active not recruiting
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma (
M21-406
)
BCL2 inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NCT05201066
Haem
Phase 2
Active not recruiting
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. (
CMBG453B12206B
)
anti-TIM3 monoclonal antibody
+ BCL2 inhibitor
Leukaemia
Myelodysplastic syndrome
VIC
3168 - Clayton - Monash Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (34)
Not yet recruiting (4)
Active not recruiting (3)
Recruitment Country and State
VIC (35)
NSW (23)
WA (18)
QLD (16)
NZ (9)
SA (5)
NT (2)
ACT (1)
TAS (1)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (15)
Phase 2 (9)
Phase 3 (4)
Trial Type
Haem (38)
Advanced (3)
Cancer Therapy Class
BCL2
100%
DNA methyltransferase
24%
BTK
22%
CD20
22%
cereblon
10%
CD38
5%
FLT3
5%
PI3K-delta
2%
CDK4
2%
CDK4 selective
2%
ER
2%
oestrogen axis
2%
CDC7
2%
KMT2A
2%
IL-6
2%
proteasome
2%
IDH1
2%
IDH1 R132
2%
AXL
2%
HDAC
2%
KIT
2%
PDGFR
2%
PKC
2%
VEGFR2
2%
PD-1
2%
PD-1/PD-L1
2%
TIM3
2%
Facility
3168 - Clayton - Monash Medical Centre (15)
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
3004 - Melbourne, Southbank - Alfred Health (11)
2139 - Concord - Concord Repatriation General Hospital (9)
6009 - Nedlands - Linear Clinical Research (8)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
6000 - Perth - Royal Perth Hospital (6)
NZ.0622 - Takapuna - North Shore Hospital (5)
2217 - Kogarah - St George Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
4217 - Benowa - Pindara Private Hospital (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2170 - Liverpool - Liverpool Hospital (2)
6005 - West Perth - Perth Blood Institute (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - One Clinical Research (2)
6168 - Cooloongup - Rockingham Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
4812 - Townsville - Townsville University Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (2)
3066 - Epping - Northern Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2500 - Wollongong - Wollongong Private Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
B-cell malignancy
Mature B-cell malignancy
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Lymphoma
Non-Hodgkin's lymphoma
B-cell lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Small Lymphocytic Lymphoma
Multiple myeloma
Plasma cell disorder
Myelodysplastic/Myeloproliferative disease
Chronic myelomonocytic leukaemia
Solid tumour
Mantle cell lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Marginal zone lymphoma
Breast adenocarcinoma
Breast cancer
HER2-negative breast cancer
Waldenström Macroglobulinaemia
Follicular lymphoma
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy